Reverb Therapeutics, a Vancouver, BC, Canada-based a leader in harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, raised USD $21M in Seed funding.
The round was led by Amplitude Ventures with participation from Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, InBC Investment Corp. (InBC), and Seido Capital.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO David de Graaf, Reverb Therapeutics is focused on expanding the therapeutic window of cytokines by harnessing the body’s own endogenous cytokines and amplifying their activity in a tissue-specific manner, leading to profound disease-modifying effects. By modulating the effects of endogenous cytokines, Reverb’s Amplify•R™ platform avoids the systemic toxicity and immunogenicity normally associated with cytokine treatments. Its bispecific antibodies amplify and redirect cytokines to tissues of interest, with potential to generate new medicines for cancer, autoimmune conditions, and other diseases.
In vivo preclinical studies have established proof-of-concept for the Amplify•R™ platform’s ability to redirect endogenous cytokines and shrink tumors. The data supports a growing body of evidence for the potency of bispecific antibodies redirecting cytokines to PD-1-positive cells. Reverb’s lead AMP01 program blocks PD-1 while delivering endogenous IL-15, a key protein that expands and activates cytotoxic T cells.
Reverb also added two new members to its board of directors:
- Maude Tessier
- Stephan Kontos
FinSMEs
19/02/2025